Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225067 | 1.00 | KCNH2 (0.65) | KCNH2 | |
| SCHEMBL5223608 | 0.92 | KCNH2 (0.66) | KCNH2 | |
| SCHEMBL5226407 | 0.88 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL5226418 | 0.88 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL5225804 | 0.87 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL5225809 | 0.87 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL6144136 | 0.86 | KCNH2 (0.59) | KCNH2 | |
| SCHEMBL6144131 | 0.86 | KCNH2 (0.59) | KCNH2 | |
| SCHEMBL5222740 | 0.86 | KCNH2 (0.72) | KCNH2 | |
| SCHEMBL5225720 | 0.86 | KCNH2 (0.72) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370550-B1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | NOVEXEL (FR) | 2007-05-23 | — | — | EP | disclosed |
| US-6815547-B2 | ANTIMICROBIAL AGENTS EFFECTIVE AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, ENTEROCOCCUS | AVENTIS PHARMA S.A. (FR) | 2004-11-09 | — | — | US | disclosed |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | AVENTIS PHARMA S.A. | 2003-09-11 | — | — | US | disclosed |
| US-6602884-B2 | Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | NOVEXEL (FR) | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | KCNH2 656/4885 |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | KCNH2 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.